Advanced search
Publication Cover
Expert Review of Clinical Immunology Volume 19, 2023 - Issue 9
Submit an article Journal homepage
236
Views
0
CrossRef citations to date
0
Altmetric
Review

Juvenile idiopathic arthritis and its associated uveitis

Arash Malekia Department of Ophthalmology, University of Florida, Gainesville, FL, USA;b Massachusetts Eye Research and Surgery Institution, Waltham, MA, USA;c The Ocular Immunology and Uveitis Foundation, Waltham, MA, USAORCID Iconhttps://orcid.org/0000-0001-5533-9798View further author information
ORCID Icon,
Priya D. Patelb Massachusetts Eye Research and Surgery Institution, Waltham, MA, USA;c The Ocular Immunology and Uveitis Foundation, Waltham, MA, USAView further author information
&
C. Steven Fosterb Massachusetts Eye Research and Surgery Institution, Waltham, MA, USA;c The Ocular Immunology and Uveitis Foundation, Waltham, MA, USA;d Department of Ophthalmology, Harvard Medical School, Boston, MA, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-6612-5653View further author information
ORCID Icon
Pages 1157-1169 | Received 23 Jan 2023, Accepted 26 Jun 2023, Published online: 04 Jul 2023

  • Petty RE, Southwood TR, Manners P, et al. International league of associations for rheumatology. International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31:390–392.
  • Prakken B, Albani S, Martini A. Juvenile idiopathic arthritis. Lancet. 2011;377:2138–2149. doi: 10.1016/S0140-6736(11)60244-4
  • Sen ES, Ramanan AV. Juvenile idiopathic arthritis-associated uveitis. Best Pract Res Clin Rheumatol. 2017;31(4):517–534. doi: 10.1016/j.berh.2018.01.002
  • Nordal E, Rypdal V, Christoffersen T, et al; Nordic Study Group of Pediatric Rheumatology (NoSPeR). Incidence and predictors of Uveitis in juvenile idiopathic arthritis in a Nordic long-term cohort study. Pediatr Rheumatol Online J. 2017;15(1):66. doi: 10.1186/s12969-017-0195-8
  • Carvounis PE, Herman DC, Cha S, et al. Incidence and outcomes of uveitis in juvenile rheumatoid arthritis, a synthesis of the literature. Graefes Arch Clin Exp Ophthalmol. 2006;244:281–290. doi: 10.1007/s00417-005-0087-3
  • Thierry S, Fautrel B, Lemelle I, et al. Prevalence and incidence of juvenile idiopathic arthritis: a systematic review. Joint Bone Spine. 2014;81:112–117. doi: 10.1016/j.jbspin.2013.09.003
  • McDougall C, Hurd K, Barnabe C. Systematic review of rheumatic disease epidemiology in the indigenous populations of Canada, the United States, Australia, and New Zealand. Semin Arthritis Rheum. 2017;46:675–686. doi: 10.1016/j.semarthrit.2016.10.010
  • Horton DB, Shenoi S. Review of environmental factors and juvenile idiopathic arthritis. Open Access Rheumatol. 2019;11:253–267. doi: 10.2147/OARRR.S165916
  • Xin L, He F, Li S, et al. Intestinal microbiota and juvenile idiopathic arthritis: current understanding and future prospective. World J Pediatr. 2021;17:40–51. doi: 10.1007/s12519-020-00371-3
  • Hayworth JL, Turk MA, Nevskaya T, et al. The frequency of uveitis in patients with juvenile inflammatory rheumatic diseases. Joint Bone Spine. 2019;86:685–690. doi: 10.1016/j.jbspin.2019.06.001
  • Sabri K, Saurenmann RK, Silverman ED, et al. Course, complications, and outcome of juvenile arthritis-related uveitis. J Aapos. 2008;12:539–545. doi: 10.1016/j.jaapos.2008.03.007
  • Angeles-Han ST, Pelajo CF, Vogler LB, et al.; CARRA Registry Investigators. Risk markers of juvenile idiopathic arthritis-associated uveitis in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry. J Rheumatol. 2013;40:2088–2096. doi: 10.3899/jrheum.130302
  • Moradi A, Amin RM, Thorne JE. The role of gender in juvenile idiopathic arthritis-associated uveitis. J Ophthalmol. 2014;2014:461078. doi: 10.1155/2014/461078
  • Päivönsalo-Hietanen T, Tuominen J, Saari KM. Uveitis in children: population-based study in Finland. Acta Ophthalmol Scand. 2000;78:84–88. doi: 10.1034/j.1600-0420.2000.078001084.x
  • Rypdal V, Glerup M, Songstad NT, et al.; Nordic Study Group of Pediatric Rheumatology. Uveitis in juvenile idiopathic arthritis: 18-year outcome in the population-based nordic cohort study. Ophthalmol. 2021;128:598–608. doi: 10.1016/j.ophtha.2020.08.024.
  • Consolaro A, Giancane G, Alongi A, et al. Paediatric rheumatology international trials organisation. Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study. Lancet Child Adolesc Health. 2019;3:255–263. doi: 10.1016/S2352-4642(19)30027-6
  • Prahalad S, Thompson SD, Conneely KN, et al. Hierarchy of risk of childhood-onset rheumatoid arthritis conferred by HLA-DRB1 alleles encoding the shared epitope. Arthritis Rheum. 2012;64(3):925–930. doi: 10.1002/art.33376
  • Ombrello MJ, Remmers EF, Tachmazidou I, de Bakker PI, Raychaudhuri S, Langefeld CD, Thompson S, Zeggini E, Thomson W, Kastner DL, Woo P, et al; British Society of Pediatric and Adolescent Rheumatology (BSPAR) Study Group; Childhood Arthritis Prospective Study (CAPS) Group; Randomized Placebo Phase Study of Rilonacept in sJIA (RAPPORT) Investigators; Sparks-Childhood Arthritis Response to Medication Study (CHARMS) Group; Biologically Based Outcome Predictors in JIA (BBOP) Group. International Childhood Arthritis Genetics (INCHARGE) Consortium. HLA-DRB1*11 and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis. Proc Natl Acad Sci U S A. 2015;112:15970–15975. doi: 10.1073/pnas.1520779112
  • Martini A, Lovell DJ, Albani S, et al. Juvenile idiopathic arthritis. Nat Rev Dis Primers. 2022;8:5. doi: 10.1038/s41572-021-00332-8
  • Burren OS, Reales G, Wong L, et al. Genetic feature engineering enables characterisation of shared risk factors in immune-mediated diseases. Genome Med. 2020;12:106. doi: 10.1186/s13073-020-00797-4
  • Haasnoot AJW, Schilham MW, Kamphuis S, Ten Cate R, de Boer JH, Pulit SL, Kuiper JJW, et al; ICON-JIA Study Group. Identification of an amino acid motif in HLA-DRβ1 That distinguishes uveitis in patients with juvenile idiopathic arthritis. Arthritis & Rheumat. 2018;70:1155–1165. doi: 10.1002/art.40484
  • Yanagimachi M, Miyamae T, Naruto T, et al. Association of HLA-A*02: 06 and HLA-DRB1*04: 05 with clinical subtypes of juvenile idiopathic arthritis. J Hum Genet. 2011;56:196–199. doi: 10.1038/jhg.2010.159
  • Pers YM, Le Blay P, Ludwig C, et al. Association of TRAF1-C5 with risk of uveitis in juvenile idiopathic arthritis. Joint Bone Spine. 2017;84:305–308. doi: 10.1016/j.jbspin.2016.04.014
  • Angeles-Han ST, Yeh S, Vogler LB. Updates on the risk markers and outcomes of severe juvenile idiopathic arthritis-associated uveitis. Int J Clin Rheumtol. 2013;8. doi: 10.2217/ijr.12.83
  • Alberdi-Saugstrup M, Enevold C, Zak M, et al.; Nordic Study Group of Pediatric Rheumatology (NoSPeR). Non-HLA gene polymorphisms in juvenile idiopathic arthritis: associations with disease outcome. Scand J Rheumatol. 2017;46:369–376. doi: 10.1080/03009742.2016.1238959
  • Wang JY, Wang WP. B7-H4, a promising target for immunotherapy. Cell Immunol. 2020;347:104008. doi: 10.1016/j.cellimm.2019.104008
  • Angeles-Han ST, Rabinovich CE. Uveitis in children. Curr Opin Rheumatol. 2016;28:544–549. doi: 10.1097/BOR.0000000000000316
  • Heiligenhaus A, Niewerth M, Ganser G, et al.; German Uveitis in Childhood Study Group. Prevalence and complications of uveitis in juvenile idiopathic arthritis in a population-based nation-wide study in Germany: suggested modification of the current screening guidelines. Rheumatology (Oxford). 2007;46:1015–1019. doi: 10.1093/rheumatology/kem053
  • Salek SS, Pradeep A, Guly C, Ramanan AV, Rosenbaum JT. Uveitis and juvenile psoriatic arthritis or psoriasis. Am J Ophthalmol. 2018;185:68–74. doi: 10.1016/j.ajo.2017.10.018
  • Baquet-Walscheid K, Rothaus K, Niewerth M, et al. Occurrence and risk factors of uveitis in juvenile psoriatic arthritis: data from a population-based nationwide study in Germany. J Rheumatol. 2022;49:719–724. doi: 10.3899/jrheum.210755
  • Weiss PF, Colbert RA. Juvenile spondyloarthritis: a distinct form of juvenile arthritis. Pediatr Clin North Am. 2018;65:675–690. doi: 10.1016/j.pcl.2018.03.006
  • American academy of pediatrics section on rheumatology and section on ophthalmology: guidelines for ophthalmologic examinations in children with juvenile rheumatoid arthritis. Pediatrics. 1993;92(2):295–296. doi: 10.1542/peds.92.2.295
  • Magni-Manzoni S, Epis O, Ravelli A, et al. Comparison of clinical versus ultrasound-determined synovitis in juvenile idiopathic arthritis. Arthritis Rheum. 2009;61:1497–1504. doi: 10.1002/art.24823
  • Janow GL, Panghaal V, Trinh A, et al. Detection of active disease in juvenile idiopathic arthritis: sensitivity and specificity of the physical examination vs ultrasound. J Rheumatol. 2011;38:2671–2674. doi: 10.3899/jrheum.110360
  • McCurdy D, Parsa MF. Updates in juvenile idiopathic arthritis. Adv Pediatr. 2021;68:143–170. doi: 10.1016/j.yapd.2021.05.014
  • Kamal S, Kumar R, Kumar S, et al. Bilateral interstitial keratitis and granulomatous uveitis of tubercular origin. Eye Contact Lens. 2014;40:e13–5. doi: 10.1097/ICL.0b013e31827a025e
  • Clarke SL, Sen ES, Ramanan AV. Juvenile idiopathic arthritis-associated uveitis. Pediatr Rheumatol Online J. 2016;14:27. doi: 10.1186/s12969-016-0088-2
  • Cunningham EJ, Rathinam SR, Tugal-Tutkun I, et al. Vogt-koyanagi-harada disease. Ocul Immunol Inflamm. 2014;22:249–252. doi: 10.3109/09273948.2014.939530
  • Wouters CH, Maes A, Foley KP, et al. Blau syndrome, the prototypic auto-inflammatory granulomatous disease. Pediatr Rheumatol Online J. 2014;12(1):33. doi: 10.1186/1546-0096-12-33
  • Rosenbaum JT, Dick AD. The eyes have it: a rheumatologist’s view of uveitis. Arthritis & Rheumat. 2018;70:1533–1543. doi: 10.1002/art.40568
  • Burke MJ, Rennebohm RM. Eye involvement in Kawasaki disease. J Pediatr Ophthalmol Strabismus. 1981;18:7–11. doi: 10.3928/0191-3913-19810901-04
  • Glerup M, Herlin T, Twilt M. Remission rate is not dependent on the presence of antinuclear antibodies in juvenile idiopathic arthritis. Clin Rheumatol. 2017;36:671–676. doi: 10.1007/s10067-017-3540-x
  • Litwin CM, Binder SR. ANA testing in the presence of acute and chronic infections. J Immunoassay Immunochem. 2016;37:439–452. doi: 10.1080/15321819.2016.1174136
  • Guillaume S, Prieur AM, Coste J, et al. Long-term outcome and prognosis in oligoarticular-onset juvenile idiopathic arthritis. Arthritis Rheum. 2000;43:1858–1865. doi: 10.1002/1529-0131(200008)43:8<1858:AID-ANR23>3.0.CO;2-A
  • Bloom JN, Ni M, Moore TL, et al. Serum antiocular antibodies in patients with juvenile rheumatoid arthritis. J Pediatr Ophthalmol Strabismus. 1993;30(4):243–248. doi: 10.3928/0191-3913-19930701-06
  • Busch M, Wefelmeyer KL, Walscheid K, et al. Identification of ocular autoantigens associated with juvenile idiopathic arthritis-associated uveitis. Front Immunol. 2019;10:1793. doi: 10.3389/fimmu.2019.01793
  • Uchiyama RC, Osborn TG, Moore TL. Antibodies to iris and retina detected in sera from patients with juvenile rheumatoid arthritis with iridocyclitis by indirect immunofluorescence studies on human eye tissue. J Rheumatol. 1989;16:1074–1078.
  • Walscheid K, Hennig M, Heinz C, et al. Correlation between disease severity and presence of ocular autoantibodies in juvenile idiopathic arthritis-associated uveitis. Invest Ophthalmol Vis Sci. 2014;55:3447–3453. doi: 10.1167/iovs.13-13444
  • Kasper M, Walscheid K, Laffer B, et al. Phenotype of Innate immune cells in uveitis associated with axial spondyloarthritis- and juvenile idiopathic arthritis-associated uveitis. Ocul Immunol Inflamm. 2021;29(6):1080–1089. doi: 10.1080/09273948.2020.1715449
  • Walscheid K, Heiligenhaus A, Holzinger D, et al. Elevated S100A8/A9 and S100A12 serum levels reflect intraocular inflammation in juvenile idiopathic arthritis-associated uveitis: results from a pilot study. Invest Ophthalmol Vis Sci. 2015;56(13):7653–7660. doi: 10.1167/iovs.15-17066
  • Angeles-Han ST, Yeh S, Patel P, et al. Discovery of tear biomarkers in children with chronic non-infectious anterior uveitis: a pilot study. J Ophthalmic Inflamm Infect. 2018;8:17. doi: 10.1186/s12348-018-0156-5
  • Petty RE, Laxer R, Lindsley C, et al. Textbook of pediatric rheumatology. 7th ed. Philadelphia: Elsevier; 2016.
  • Pascual V, Allantaz F, Arce E, et al. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med. 2005;201:1479–1486. doi: 10.1084/jem.20050473
  • Ogilvie EM, Khan A, Hubank M, et al. Specific gene expression profiles in systemic juvenile idiopathic arthritis. Arthritis Rheum. 2007;56:1954–1965. doi: 10.1002/art.22644
  • Tse SML, Petty RE. Enthesitis related arthritis. In: RE LP, Laxer R Lindsley C, editors. Textbook of pediatric rheumatology. 7th ed. Philadelphia: Elsevier; 2016. p. 238–255.e6. doi: 10.1016/B978-0-323-24145-8.00019-3
  • Lindsley CB, Laxer RM. Arthropathies of inflammatory bowel disease. In: RE LP, Laxer R Lindsley C, editors. Textbook of pediatric rheumatology. 7th ed. Philadelphia: Elsevier; 2016. p. 268–273.e2. doi: 10.1016/B978-0-323-24145-8.00021-1
  • Ruperto N, Nikishina I, Pachanov ED, et al.; Pediatric Rheumatology International Trials Organization. A randomized, double-blind clinical trial of two doses of meloxicam compared with naproxen in children with juvenile idiopathic arthritis: short- and long-term efficacy and safety results. Arthritis Rheum. 2005;52:563–572. doi: 10.1002/art.20860
  • Reiff A, Lovell DJ, Adelsberg JV, et al. Evaluation of the comparative efficacy and tolerability of rofecoxib and naproxen in children and adolescents with juvenile rheumatoid arthritis: a 12-week randomized controlled clinical trial with a 52-week open-label extension. J Rheumatol. 2006;33:985–995.
  • Ravelli A, Lattanzi B, Consolaro A, et al. Glucocorticoids in paediatric rheumatology. Clin Exp Rheumatol. 2011;29:S148–52.
  • Zulian F, Martini G, Gobber D, et al. Comparison of intra-articular triamcinolone hexacetonide and triamcinolone acetonide in oligoarticular juvenile idiopathic arthritis. Rheumatology (Oxford). 2003;42:1254–1259. doi: 10.1093/rheumatology/keg358
  • Zulian F, Martini G, Gobber D, et al. Triamcinolone acetonide and hexacetonide intra-articular treatment of symmetrical joints in juvenile idiopathic arthritis: a double-blind trial. Rheumatology (Oxford). 2004;43:1288–1291. doi: 10.1093/rheumatology/keh313
  • Ravelli A, Davì S, Bracciolini G, et al.; Italian Pediatric Rheumatology Study Group. Intra-articular corticosteroids versus intra-articular corticosteroids plus methotrexate in oligoarticular juvenile idiopathic arthritis: a multicentre, prospective, randomised, open-label trial. Lancet. 2017;389:909–916. doi: 10.1016/S0140-6736(17)30065-X
  • Martini A, Lovell DJ. Juvenile idiopathic arthritis: state of the art and future perspectives. Ann Rheum Dis. 2010;69:1260–1263. doi: 10.1136/ard.2010.133033
  • Ruperto N, Martini A. Emerging drugs to treat juvenile idiopathic arthritis. Expert Opin Emerg Drugs. 2011;16:493–505. doi: 10.1517/14728214.2011.581662
  • Ruperto N, Quartier P, Wulffraat N, et al. Paediatric Rheumatology International Clinical Trials Organisation. A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis Rheum. 2012;64:557–567. doi: 10.1002/art.33342
  • Nigrovic PA, Mannion M, Prince FH, et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum. 2011;63:545–555. doi: 10.1002/art.30128
  • Vastert SJ, de Jager W, Noordman BJ, et al. Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study. Arthritis & rheumat. 2014;66:1034–1043. doi: 10.1002/art.38296
  • Ter Haar NM, van Dijkhuizen EHP, Swart JF, et al. Treatment to target using recombinant interleukin-1 receptor antagonist as first-line monotherapy in new-onset systemic juvenile idiopathic arthritis: results from a five-year follow-up study. Arthritis & rheumat. 2019;71:1163–1173. doi: 10.1002/art.40865
  • Quartier P, Alexeeva E, Constantin T, et al.; Paediatric Rheumatology International Trials Organisation and the Pediatric Rheumatology Collaborative Study Group. Tapering canakinumab monotherapy in patients with systemic juvenile idiopathic arthritis in clinical remission: results from a phase IIIb/IV open-label, randomized study. Arthritis & rheumat. 2021;73:336–346. doi: 10.1002/art.41488
  • De Benedetti F, Brunner HI, Ruperto N, et al.; PRINTO; PRCSG. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367:2385–2395. doi: 10.1056/NEJMoa1112802.
  • Yokota S, Imagawa T, Mori M, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008;371:998–1006. doi: 10.1016/S0140-6736(08)60454-7
  • Nigrovic PA. Review: is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis? Arthritis & Rheumat. 2014;66:1405–1413. doi: 10.1002/art.38615
  • Foell D, Wulffraat N, Wedderburn LR, et al.; Paediatric Rheumatology International Trials Organization (PRINTO). Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial. JAMA. 2010;303(13):1266–1273. Erratum in: JAMA. 2010;303:2034. doi: 10.1001/jama.2010.375
  • Giancane G, Ruperto N; Paediatric Rheumatology International Trials Organisation (PRINTO). Treatment of juvenile idiopathic arthritis: what’s new? Curr Opin Rheumatol. 2019;31:428–435. doi: 10.1097/BOR.0000000000000632
  • Lovell DJ, Ruperto N, Goodman S, et al; Pediatric Rheumatology Collaborative Study Group; Pediatric Rheumatology International Trials Organisation. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008;359(8):810–820. doi: 10.1056/NEJMoa0706290
  • Horneff G, Fitter S, Foeldvari I, et al. Double-blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short-term improvement. Arthritis Res Ther. 2012;14:R230.
  • Brunner HI, Ruperto N, Tzaribachev N, et al, Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG). Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial. Ann Rheum Dis. 2018;77(1):21–29. doi: 10.1136/annrheumdis-2016-210456
  • Ruperto N, Brunner HI, Pacheco-Tena C, et al; Pediatric Rheumatology Collaborative Study Group (PRCSG) and the Paediatric Rheumatology International Trials Organisation (PRINTO). Open-label phase 3 study of intravenous golimumab in patients with polyarticular juvenile idiopathic arthritis. Rheumatology (Oxford). 2021;60(10):4495–4507. doi: 10.1093/rheumatology/keab021
  • Ruperto N, Lovell DJ, Cuttica R, et al.; Paediatric Rheumatology International Trials Organisation; Pediatric Rheumatology Collaborative Study Group. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum. 2007;56:3096–3106. doi: 10.1002/art.22838
  • Ruperto N, Brunner HI, Ramanan AV, et al.; Paediatric Rheumatology INternational Trials Organisation (PRINTO) and the Paediatric Rheumatology Collaborative Study Group (PRCSG). Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis. Rheumatology (Oxford). 2021;60:4568–4580. doi: 10.1093/rheumatology/keab047
  • Brunner HI, Ruperto N, Zuber Z, et al.; Paediatric Rheumatology International Trials Organisation PRINTO; Pediatric Rheumatology Collaborative Study Group (PRCSG). Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. Ann Rheum Dis. 2015;74:1110–1117. doi: 10.1136/annrheumdis-2014-205351
  • Bharucha KN, Brunner HI, Calvo Penadés I, et al.; Paediatric Rheumatology International Trials Organisation and the Pediatric Rheumatology Collaborative Study Group. Growth during tocilizumab therapy for polyarticular-course juvenile idiopathic arthritis: 2-year data from a phase III clinical trial. J Rheumatol. 2018;45:1173–1179. doi: 10.3899/jrheum.170326
  • Malattia C, Ruperto N, Pederzoli S, et al.; Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG). Tocilizumab may slow radiographic progression in patients with systemic or polyarticular-course juvenile idiopathic arthritis: post hoc radiographic analysis from two randomized controlled trials. Arthritis Res Ther. 2020;22:211. doi: 10.1186/s13075-020-02303-y
  • Ruperto N, Lovell DJ, Quartier P, et al; Paediatric Rheumatology INternational Trials Organization; Pediatric Rheumatology Collaborative Study Group. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet. 2008;372(9636):383–391. doi: 10.1016/S0140-6736(08)60998-8
  • Brunner HI, Tzaribachev N, Vega-Cornejo G; Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG). Subcutaneous Abatacept in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase III open-label study. Arthritis & Rheumat. 2018;70(7):1144–1154. doi: 10.1002/art.40466
  • Ruperto N, Brunner HI, Zuber Z, et al.; Pediatric Rheumatology International Trials Organization (PRINTO); Pediatric Rheumatology Collaborative Study Group (PRCSG). Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study. Pediatr Rheumatol Online J. 2017;15:86. doi: 10.1186/s12969-017-0212-y
  • Ruperto N, Brunner HI, Synoverska O, et al.; Paediatric Rheumatology International Trials Organisation (PRINTO) and Pediatric Rheumatology Collaborative Study Group (PRCSG). Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial. Lancet. 2021;398:1984–1996. doi: 10.1016/S0140-6736(21)01255-1
  • Paroli M, Spadea L, Caccavale R, et al. The role of interleukin-17 in juvenile idiopathic arthritis: from pathogenesis to treatment. Med (Kaunas). 2022;58:1552. doi: 10.3390/medicina58111552
  • Ferrara G, Mastrangelo G, Barone P, et al.; Rheumatology Italian Study Group. Methotrexate in juvenile idiopathic arthritis: advice and recommendations from the MARAJIA expert consensus meeting. Pediatr Rheumatol Online J. 2018;16:46. doi: 10.1186/s12969-018-0255-8
  • Murdaca G, Negrini S, Magnani O, et al. Update upon efficacy and safety of etanercept for the treatment of spondyloarthritis and juvenile idiopathic arthritis. Mod Rheumatol. 2018;28:417–431. doi: 10.1080/14397595.2017.1366006
  • LaMattina KC, Koreishi AF. What is new in paediatric uveitis? Curr Opin Ophthalmol. 2018;29:412–418. doi: 10.1097/ICU.0000000000000501
  • Murdaca G, Colombo BM, Puppo F. Adalimumab for the treatment of immune-mediated diseases: an update on old and recent indications. Drugs Today (Barc). 2011;47:277–288. doi: 10.1358/dot.2011.47.4.1576692
  • Ramanan AV, Dick AD, Jones AP, et al.; SYCAMORE Study Group. Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis. N Engl J Med. 2017;376:1637–1646. doi: 10.1056/NEJMoa1614160
  • Quartier P, Baptiste A, Despert V, et al.; ADJUVITE Study Group. ADJUVITE: a double-blind, randomised, placebo-controlled trial of adalimumab in early onset, chronic, juvenile idiopathic arthritis-associated anterior uveitis. Ann Rheum Dis. 2018;77:1003–1011. doi: 10.1136/annrheumdis-2017-212089
  • Cecchin V, Zannin ME, Ferrari D, et al. Longterm safety and efficacy of adalimumab and infliximab for uveitis associated with juvenile idiopathic arthritis. J Rheumatol. 2018;45:1167–1172. doi: 10.3899/jrheum.171006
  • Leinonen ST, Aalto K, Kotaniemi KM, et al. Anti-adalimumab antibodies in juvenile idiopathic arthritis-related uveitis. Clin Exp Rheumatol. 2017;35:1043–1046.
  • Palmou-Fontana N, Calvo-Río V, Martín-Varillas JL, et al. Golimumab in refractory uveitis associated to juvenile idiopathic arthritis: multicentre study of 7 cases and literature review. Clin Exp Rheumatol. 2018;36:652–657.
  • Tappeiner C, Mesquida M, Adán A, et al. Evidence for tocilizumab as a treatment option in refractory uveitis associated with juvenile idiopathic arthritis. J Rheumatol. 2016;43:2183–2188. doi: 10.3899/jrheum.160231
  • Calvo-Río V, Santos-Gómez M, Calvo I, et al. Anti-interleukin-6 receptor tocilizumab for severe juvenile idiopathic arthritis-associated uveitis refractory to anti-tumor necrosis factor therapy: a multicenter study of twenty-five patients. Arthritis & rheumat. 2017;69:668–675. doi: 10.1002/art.39940
  • Mesquida M, Molins B, Llorenç V, et al. Twenty-four month follow-up of tocilizumab therapy for refractory uveitis-related macular edema. Retina. 2018;38:1361–1370. doi: 10.1097/IAE.0000000000001690
  • Pleyer U, Algharably EA, Feist E, et al. Small molecules as therapy for uveitis: a selected perspective of new and developing agents. Expert Opin Pharmacother. 2017;18:1311–1323. doi: 10.1080/14656566.2017.1361408
  • Minden K. Adult outcomes of patients with juvenile idiopathic arthritis. Horm Res. 2009; 72(Suppl 1):20–25. doi: 10.1159/000229759
  • Selvaag AM, Aulie HA, Lilleby V, et al. Disease progression into adulthood and predictors of long-term active disease in juvenile idiopathic arthritis. Ann Rheum Dis. 2016;75:190–195. doi: 10.1136/annrheumdis-2014-206034
  • Oen K, Malleson PN, Cabral DA, et al. Disease course and outcome of juvenile rheumatoid arthritis in a multicenter cohort. J Rheumatol. 2002;29:1989–1999.
  • Anink J, Prince FH, Dijkstra M, et al. Long-term quality of life and functional outcome of patients with juvenile idiopathic arthritis in the biologic era: a longitudinal follow-up study in the Dutch arthritis and biologicals in children register. Rheumatology (Oxford). 2015;54:1964–1969. doi: 10.1093/rheumatology/kev195
  • Minoia F, Davì S, Horne A, et al.; Pediatric Rheumatology International Trials Organization; Childhood Arthritis and Rheumatology Research Alliance; Pediatric Rheumatology Collaborative Study Group; Histiocyte Society. Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients. Arthritis & rheumat. 2014;66:3160–3169. doi: 10.1002/art.38802
  • Stagi S, Cavalli L, Signorini C, et al. Bone mass and quality in patients with juvenile idiopathic arthritis: longitudinal evaluation of bone-mass determinants by using dual-energy x-ray absorptiometry, peripheral quantitative computed tomography, and quantitative ultrasonography. Arthritis Res Ther. 2014;16:R83. doi: 10.1186/ar4525
  • Barišić Kutija M, Perić S, Knežević J, et al. Complication and prognosis of juvenile idiopathic arthritis associated uveitis in the era of modern immunomodulatory treatment. Psychiatry Danub. 2019;31:44–49.
  • Angeles-Han ST, Ringold S, Beukelman T, et al. 2019 American College of Rheumatology/Arthritis foundation guideline for the screening, monitoring, and treatment of juvenile idiopathic arthritis-associated uveitis. Arthritis Care Res (Hoboken). Jun 2019;71:703–716. doi: 10.1002/acr.23871
  • Filocamo G, Consolaro A, Schiappapietra B, et al. A new approach to clinical care of juvenile idiopathic arthritis: the Juvenile arthritis multidimensional assessment report. J Rheumatol. 2011;38:938–953. doi: 10.3899/jrheum.100930
  • Sestan M, Grguric D, Sedmak M, et al. Quality of life in children suffering from juvenile idiopathic arthritis-associated uveitis. Rheumatol Int. 2020;40:1117–1121. doi: 10.1007/s00296-020-04536-1
  • Angeles-Han ST, Griffin KW, Harrison MJ, et al. Development of a vision-related quality of life instrument for children ages 8-18 years for use in juvenile idiopathic arthritis-associated uveitis. Arthritis Care Res (Hoboken). 2011;63:1254–1261. doi: 10.1002/acr.20524
  • Angeles-Han ST, Ringold S, Beukelman T, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis. Arthritis Care Res (Hoboken). 2019;71:703–716. doi: 10.1002/acr.23871
  • Angeles-Han ST, Yeh S, McCracken C, et al. Using the effects of youngsters’ eyesight on quality of life questionnaire to measure visual outcomes in children with uveitis. Arthritis Care Res (Hoboken). 2015;67:1513–1520. doi: 10.1002/acr.22627
  • Foeldvari I, Klotsche J, Simonini G, et al. Proposal for a definition for response to treatment, inactive disease and damage for JIA-associated uveitis based on the validation of a uveitis related JIA outcome measures from the Multinational Interdisciplinary Working Group for Uveitis in Childhood (MIWGUC). Pediatr Rheumatol Online J. 2019;17:66. doi: 10.1186/s12969-019-0345-2
  • Murdaca G, Colombo BM, Cagnati P, et al. Endothelial dysfunction in rheumatic autoimmune diseases. Atherosclerosis. 2012;224:309–317. doi: 10.1016/j.atherosclerosis.2012.05.013
  • Murdaca G, Spanò F, Cagnati P, et al. Free radicals and endothelial dysfunction: potential positive effects of TNF-α inhibitors. Redox Rep. 2013;18:95–99. doi: 10.1179/1351000213Y.0000000046
  • Murdaca G, Spanò F, Contatore M, et al. Pharmacogenetics of etanercept: role of TNF-α gene polymorphisms in improving its efficacy. Expert Opin Drug Metab Toxicol. 2014;10:1703–1710. doi: 10.1517/17425255.2014.970165
  • Louis E, Franchimont D, Piron A, et al. Tumour necrosis factor (TNF) gene polymorphism influences TNF-alpha production in lipopolysaccharide (LPS)-stimulated whole blood cell culture in healthy humans. Clin Exp Immunol. 1998;113:401–406. doi: 10.1046/j.1365-2249.1998.00662.x
  • Minozzi S, Bonovas S, Lytras T, et al. Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. Expert Opin Drug Saf. 2016;15:11–34. doi: 10.1080/14740338.2016.1240783
  • Murdaca G, Negrini S, Pellecchio M, Greco M, Schiavi C, Giusti F, Puppo F. Update upon the infection risk in patients receiving TNF alpha inhibitors. Expert Opin Drug Saf. 2019;18(3):219–229. doi: 10.1080/14740338.2019.1577817
  • Di Salvo E, Ventura-Spagnolo E, Casciaro M, et al. IL-33/IL-31 axis: a potential inflammatory pathway. Mediators Inflamm. 2018;2018:3858032. doi: 10.1155/2018/3858032
  • Filaci G, Rizzi M, Setti M, et al. Non-antigen-specific CD8(+) T suppressor lymphocytes in diseases characterized by chronic immune responses and inflammation. Ann N Y Acad Sci. 2005;1050:115–123. doi: 10.1196/annals.1313.013

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.